Free Trial
NASDAQ:FBLG

FibroBiologics Q3 2025 Earnings Report

FibroBiologics logo
$1.16 +0.03 (+2.65%)
Closing price 04:00 PM Eastern
Extended Trading
$1.14 -0.02 (-1.64%)
As of 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

FibroBiologics EPS Results

Actual EPS
-$2.60
Consensus EPS
-$2.00
Beat/Miss
Missed by -$0.60
One Year Ago EPS
N/A

FibroBiologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

FibroBiologics Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
Friday, October 31, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

FibroBiologics' Q2 2026 earnings is estimated for Thursday, July 30, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

FibroBiologics Earnings Headlines

FibroBiologics (NASDAQ:FBLG) Shares Up 5.7% - Should You Buy?
Goldman Sachs just told you what to buy (most people missed it)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.tc pixel
See More FibroBiologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like FibroBiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on FibroBiologics and other key companies, straight to your email.

About FibroBiologics

FibroBiologics (NASDAQ:FBLG), Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

View FibroBiologics Profile